2 results
Approved WMOPending
This study aims to evaluate IDRX-42 administered to participants with metastatic and/or surgically unresectable GIST.
Approved WMOCompleted
The primary objective is to compare doxorubicin plus olaratumab versus doxorubicin plus placebo with respect to OS in patients with advanced or metastatic soft tissue sarcoma (STS) or advanced or metastatic leiomyosarcoma (LMS), not amenable to…